Trial site
Azienda Ospedaliera Regionale San Carlo
Potenza, 85100, ItalyNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 210 trials
- Phase 37 trials
- Phase 2/31 trial
- Status
- Recruiting8 trials
- Active, not recruiting7 trials
- Completed1 trial
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- IRCCS Istituto Nazionale Tumori Fondazione Pascale3 trials
- Fondazione Italiana Linfomi - ETS2 trials
- National Cancer Institute, Naples2 trials
- Vertex Pharmaceuticals Incorporated2 trials
- AstraZeneca1 trial
- and 8 more
Running trials
Recruiting
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
NCT07213570· Phase 2· National Cancer Institute, Naples· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
NCT06714357· Phase 2· National Cancer Institute, Naples· Source
Recruiting
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)
2023-509551-14-00· Phase 3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study
2023-506662-31-00· Phase 2· Fondazione GONO G.I.· Source
Active, not recruiting
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· Phase 2· Consorzio Oncotech· Source
Active, not recruiting
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Active, not recruiting
Adjuvant therapy in stage IV colorectal cancer patients NED
2024-518217-26-00· Phase 2· IRCCS Ospedale Policlinico San Martino· Source
Active, not recruiting
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
NCT05312398· Phase 2· University of Campania Luigi Vanvitelli· Source
Recruiting
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD/AIRO-GI) randomised clinical trial. The NeoAspMet trial
2024-519007-10-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)
NCT03731234· Phase 2· Fondazione Italiana Linfomi Ets· Source
Active, not recruiting
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer
2024-516844-25-01· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error